LEGN Stock Analysis: Legend Biotech | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.786m USD | 12M Return: -30.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 59.3M
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Legend Biotech Corporation (LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey, that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other diseases across the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy designed to treat multiple myeloma (MM).
The companys pipeline extends beyond cilta-cel to include earlier-stage autologous CAR-T candidates targeting cancers such as acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, and lung cancers, as well as allogeneic gamma delta CAR-T and CAR-NK product candidates directed at B-cell maturation antigen (BCMA) for MM, which are currently in investigator-initiated Phase 1 trials in China. Legend Biotech operates within a capital-intensive business model typical of the biotechnology sector, relying heavily on R&D investment, multi-year clinical development timelines, and regulatory approvals to bring therapies to market.
Key partnerships include a collaboration and license agreement with Janssen Biotech for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for CAR-T cell therapies targeting delta-like ligand protein 3 (DLL3). The company went public on NASDAQ in June 2020 and is classified in the Health Care sector under the Biotechnology sub-industry.
- Carvykti sales surge as multiple myeloma demand expands
- Janssen partnership fuels global cilta-cel commercialization
- Abecma competition intensifies in BCMA-directed therapy market
| Net Income: -250.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 50.37% < 20% (prev 135.2%; Δ -84.80% < -1%) |
| CFO/TA -0.11 > 3% & CFO -175.2m > Net Income -250.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (184.7m) vs 12m ago 0.53% < -2% |
| Gross Margin: 54.99% > 18% (prev 65.51%; Δ -10.53% > 0.5%) |
| Asset Turnover: 70.90% > 50% (prev 45.08%; Δ 25.83% > 0%) |
| Interest Coverage Ratio: -10.08 > 6 (EBIT TTM -220.4m / Interest Expense TTM 21.9m) |
| A: 0.36 (Total Current Assets 1.08b - Total Current Liabilities 509.1m) / Total Assets 1.60b |
| B: -1.26 (Retained Earnings -2.01b / Total Assets 1.60b) |
| C: -0.14 (EBIT TTM -220.4m / Avg Total Assets 1.61b) |
| D: 1.54 (Book Value of Equity 967.7m / Total Liabilities 629.0m) |
| Altman-Z'' = -1.06 = CCC |
| DSRI: 0.72 (Receivables 186.6m/166.8m, Revenue 1.14b/728.3m) |
| GMI: 1.19 (GM 65.51% / 54.99%) |
| AQI: 0.33 (AQ_t 0.04 / AQ_t-1 0.12) |
| SGI: 1.56 (Revenue 1.14b / 728.3m) |
| TATA: -0.05 (NI -250.2m - CFO -175.2m) / TA 1.60b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 27.38 with a total of 1,389,900 shares traded. Over the past week, the price has changed by -8.40%, over one month by -18.24%, over three months by +50.44% and over the past year by -30.60%.
Current recommended Stop Loss: 25.10 (which is 8.3% or 1.2 ATR below the current price).
Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
- StrongBuy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 57.2 | 109.1% |
P/E Forward = 232.5581
P/S = 5.0797
P/B = 5.9829
Revenue TTM = 1.14b USD
EBIT TTM = -220.4m USD
EBITDA TTM = -181.1m USD
Long Term Debt = 112.1m USD (estimated: total debt 389.3m - short term 277.2m)
Short Term Debt = 277.2m USD (from shortTermDebt, last quarter)
Debt = 512.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 123.3m
Net Debt = -322.0m USD (calculated: Debt 512.6m - CCE 834.6m)
Enterprise Value = 5.46b USD (5.79b + Debt 512.6m - CCE 834.6m)
Interest Coverage Ratio = -10.08 (Ebit TTM -220.4m / Interest Expense TTM 21.9m)
EV/FCF = -23.12x (Enterprise Value 5.46b / FCF TTM -236.4m)
FCF Yield = -4.33% (FCF TTM -236.4m / Enterprise Value 5.46b)
FCF Margin = -20.75% (FCF TTM -236.4m / Revenue TTM 1.14b)
Net Margin = -21.97% (Net Income TTM -250.2m / Revenue TTM 1.14b)
Gross Margin = 54.99% ((Revenue TTM 1.14b - Cost of Revenue TTM 512.7m) / Revenue TTM)
Gross Margin QoQ = 42.35% (prev 59.70%)
Tobins Q-Ratio = 3.42 (Enterprise Value 5.46b / Total Assets 1.60b)
Interest Expense / Debt = 4.27% (Interest Expense 21.9m / Debt 512.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -174.1m (EBIT -220.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.13 (Total Current Assets 1.08b / Total Current Liabilities 509.1m)
Debt / Equity = 0.53 (Debt 512.6m / totalStockholderEquity, last quarter 967.7m)
Debt / EBITDA = 1.78 (negative EBITDA) (Net Debt -322.0m / EBITDA -181.1m)
Debt / FCF = 1.36 (negative FCF - burning cash) (Net Debt -322.0m / FCF TTM -236.4m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -15.58% (Net Income -250.2m / Total Assets 1.60b)
RoE = -24.91% (Net Income TTM -250.2m / Total Stockholder Equity 1.00b)
RoCE = -19.74% (EBIT -220.4m / Capital Employed (Equity 1.00b + L.T.Debt 112.1m))
RoIC = -13.31% (negative operating profit) (NOPAT -174.1m / Invested Capital 1.31b)
WACC = 8.01% (E(5.79b)/V(6.30b) * Re(8.42%) + D(512.6m)/V(6.30b) * Rd(4.27%) * (1-Tc(0.21)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 0.69%
[DCF] Fair Price = unknown (Cash Flow -236.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: 98.61 | Revenue CAGR: 97.20% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.28 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.28 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+117.5% | GrowthRev=+38.2%
EPS next Year (2027-12-31): EPS=1.30 | Chg30d=+4.62% | Revisions=+0% | GrowthEPS=+345.6% | GrowthRev=+25.9%
[Analyst] Revisions Ratio: +0% (up=0, down=0)